MWNA
EVLO

Marshall Wace North America’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Marshall Wace North America’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-109
Closed -$18K – 1742
2019
Q1 		$18K Buy
+109
New +$21.6K ﹤0.01% 1398

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Marshall Wace North America's EVLO Position: Q2 2019 in Review

Marshall Wace North America sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2019, closing a stake of 109 shares — an estimated $18K sold.

Marshall Wace North America first reported a position in EVLO in Q1 2019 and held it in 1 quarter. The position peaked at $18K in Q1 2019. 38 funds tracked by Wall St. Rank hold EVLO as of Q2 2019.

  • Marshall Wace North America reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 109 Evelo Biosciences, Inc. Common Stock shares in Q2 2019, an estimated $18K.
  • Marshall Wace North America first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Marshall Wace North America's Evelo Biosciences, Inc. Common Stock position peaked at $18K in Q1 2019.
  • 38 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.